1. Home
  2. Pharma & Healthcare
  3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth (Status and Outlook) 2020-2025

Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth (Status and Outlook) 2020-2025

Publication Month: Apr 2020 | No. of Pages: 0 Published By: LP Information
Single User License: US $ 3660
Corporate User License: US $ 7320

COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

According to this latest study, the 2020 growth of Drugs for Duchenne Muscular Dystrophy (DMD) will have significant change from previous year. By the most conservative estimates of global Drugs for Duchenne Muscular Dystrophy (DMD) market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Drugs for Duchenne Muscular Dystrophy (DMD) market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Duchenne Muscular Dystrophy (DMD) market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Drugs for Duchenne Muscular Dystrophy (DMD), covering the supply chain analysis, impact assessment to the Drugs for Duchenne Muscular Dystrophy (DMD) market size growth rate in several scenarios, and the measures to be undertaken by Drugs for Duchenne Muscular Dystrophy (DMD) companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.
Eteplirsen
Deflazacort
Ataluren

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.
Hospitals
Clinics
Home Care

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Sarepta Therapeutics
PTC Therapeutics
Bristol-Myers Squibb
Italfarmaco
Pfizer
Santhera Pharmaceuticals
WaVe life Science
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Drugs for Duchenne Muscular Dystrophy (DMD) market size by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Drugs for Duchenne Muscular Dystrophy (DMD) market by identifying its various subsegments.
Focuses on the key global Drugs for Duchenne Muscular Dystrophy (DMD) players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Duchenne Muscular Dystrophy (DMD) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Drugs for Duchenne Muscular Dystrophy (DMD) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
1.7 What is the Impact of Covid-19 Outbreak On the Drugs for Duchenne Muscular Dystrophy (DMD)?
1.7.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.7.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.7.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size in 2020, by Scenario
1.7.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2015-2025
2.1.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size CAGR by Region
2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
2.2.1 Eteplirsen
2.2.2 Eteplirsen
2.2.3 Ataluren
2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
2.3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2015-2020)
2.3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Type (2015-2020)
2.4 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
2.5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application (2015-2020)
2.5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate by Application (2015-2020)

3 Global Drugs for Duchenne Muscular Dystrophy (DMD) by Players
3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Players
3.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Players (2018-2020)
3.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Players (2018-2020)
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Drugs for Duchenne Muscular Dystrophy (DMD) by Regions
4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions
4.2 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth
4.3 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth
4.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth
4.5 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth

5 Americas
5.1 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Countries
5.2 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
5.3 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions
6.2 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
6.3 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) by Countries
7.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
7.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) by Countries
8.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
8.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast (2021-2025)
10.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Regions
10.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Regions (2021-2025)
10.2.2 Americas Market Forecast
10.2.3 APAC Market Forecast
10.2.4 Europe Market Forecast
10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
10.3.1 United States Market Forecast
10.3.2 Canada Market Forecast
10.3.3 Mexico Market Forecast
10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
10.4.1 China Market Forecast
10.4.2 Japan Market Forecast
10.4.3 Korea Market Forecast
10.4.4 Southeast Asia Market Forecast
10.4.5 India Market Forecast
10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
10.5.1 Germany Market Forecast
10.5.2 France Market Forecast
10.5.3 UK Market Forecast
10.5.4 Italy Market Forecast
10.5.5 Russia Market Forecast
10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
10.6.1 Egypt Market Forecast
10.6.2 South Africa Market Forecast
10.6.3 Israel Market Forecast
10.6.4 Turkey Market Forecast
10.6.5 GCC Countries Market Forecast
10.7 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Type
10.8 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Application

11 Key Players Analysis
11.1 Sarepta Therapeutics
11.1.1 Company Details
11.1.2 Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2020)
11.1.4 Main Business Overview
11.1.5 Sarepta Therapeutics News
11.2 PTC Therapeutics
11.2.1 Company Details
11.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2020)
11.2.4 Main Business Overview
11.2.5 PTC Therapeutics News
11.3 Bristol-Myers Squibb
11.3.1 Company Details
11.3.2 Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.3.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2020)
11.3.4 Main Business Overview
11.3.5 Bristol-Myers Squibb News
11.4 Italfarmaco
11.4.1 Company Details
11.4.2 Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.4.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2020)
11.4.4 Main Business Overview
11.4.5 Italfarmaco News
11.5 Pfizer
11.5.1 Company Details
11.5.2 Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.5.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2020)
11.5.4 Main Business Overview
11.5.5 Pfizer News
11.6 Santhera Pharmaceuticals
11.6.1 Company Details
11.6.2 Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2020)
11.6.4 Main Business Overview
11.6.5 Santhera Pharmaceuticals News
11.7 WaVe life Science
11.7.1 Company Details
11.7.2 Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2020)
11.7.4 Main Business Overview
11.7.5 WaVe life Science News
...

12 Research Findings and Conclusion

Tables and Figures

List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Drugs for Duchenne Muscular Dystrophy (DMD) Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Eteplirsen
Table 7. Major Players of Deflazacort
Table 8. Major Players of Ataluren
Table 9. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2014-2019) ($ Millions)
Table 10. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2015-2020)
Table 11. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2015-2020) ($ Millions)
Table 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application (2015-2020)
Table 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players (2018-2020) ($ Millions)
Table 14. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2018-2020)
Table 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Head office and Products Offered
Table 16. Drugs for Duchenne Muscular Dystrophy (DMD) Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions 2015-2020 ($ Millions)
Table 20. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Regions 2015-2020
Table 21. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Countries (2015-2020) ($ Millions)
Table 22. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Countries (2015-2020)
Table 23. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2015-2020) ($ Millions)
Table 24. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2015-2020)
Table 25. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2015-2020) ($ Millions)
Table 26. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application (2015-2020)
Table 27. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions (2015-2020) ($ Millions)
Table 28. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Regions (2015-2020)
Table 29. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2015-2020) ($ Millions)
Table 30. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2015-2020)
Table 31. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2015-2020) ($ Millions)
Table 32. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application (2015-2020)
Table 33. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Countries (2015-2020) ($ Millions)
Table 34. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Countries (2015-2020)
Table 35. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2015-2020) ($ Millions)
Table 36. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2015-2020)
Table 37. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2015-2020) ($ Millions)
Table 38. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application (2015-2020)
Table 39. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Countries (2015-2020) ($ Millions)
Table 40. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Countries (2015-2020)
Table 41. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2015-2020) ($ Millions)
Table 42. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2015-2020)
Table 43. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2015-2020) ($ Millions)
Table 44. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application (2015-2020)
Table 45. Key and Potential Regions of Drugs for Duchenne Muscular Dystrophy (DMD)
Table 46. Key Application and Potential Industries of Drugs for Duchenne Muscular Dystrophy (DMD)
Table 47. Key Challenges of Drugs for Duchenne Muscular Dystrophy (DMD)
Table 48. Key Trends of Drugs for Duchenne Muscular Dystrophy (DMD)
Table 49. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Regions (2021-2025) ($ Millions)
Table 50. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share Forecast by Regions
Table 51. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2021-2025) ($ Millions)
Table 52. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share Forecast by Type (2021-2025)
Table 53. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Application (2021-2025) ($ Millions)
Table 54. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share Forecast by Application (2021-2025)
Table 55. Sarepta Therapeutics Details, Company Total Revenue (in $ million), Head Office, Drugs for Duchenne Muscular Dystrophy (DMD) Major Market Areas and Its Competitors
Table 56. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
Table 57. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2018-2020E)
Table 58. Sarepta Therapeutics Main Business
Table 59. Sarepta Therapeutics Latest Developments
Table 60. PTC Therapeutics Details, Company Total Revenue (in $ million), Head Office, Drugs for Duchenne Muscular Dystrophy (DMD) Major Market Areas and Its Competitors
Table 61. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
Table 62. PTC Therapeutics Main Business
Table 63. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2018-2020E)
Table 64. PTC Therapeutics Latest Developments
Table 65. Bristol-Myers Squibb Details, Company Total Revenue (in $ million), Head Office, Drugs for Duchenne Muscular Dystrophy (DMD) Major Market Areas and Its Competitors
Table 66. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
Table 67. Bristol-Myers Squibb Main Business
Table 68. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2018-2020E)
Table 69. Bristol-Myers Squibb Latest Developments
Table 70. Italfarmaco Details, Company Total Revenue (in $ million), Head Office, Drugs for Duchenne Muscular Dystrophy (DMD) Major Market Areas and Its Competitors
Table 71. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
Table 72. Italfarmaco Main Business
Table 73. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2018-2020E)
Table 74. Italfarmaco Latest Developments
Table 75. Pfizer Details, Company Total Revenue (in $ million), Head Office, Drugs for Duchenne Muscular Dystrophy (DMD) Major Market Areas and Its Competitors
Table 76. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
Table 77. Pfizer Main Business
Table 78. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2018-2020E)
Table 79. Pfizer Latest Developments
Table 80. Santhera Pharmaceuticals Details, Company Total Revenue (in $ million), Head Office, Drugs for Duchenne Muscular Dystrophy (DMD) Major Market Areas and Its Competitors
Table 81. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
Table 82. Santhera Pharmaceuticals Main Business
Table 83. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2018-2020E)
Table 84. Santhera Pharmaceuticals Latest Developments
Table 85. WaVe life Science Details, Company Total Revenue (in $ million), Head Office, Drugs for Duchenne Muscular Dystrophy (DMD) Major Market Areas and Its Competitors
Table 86. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
Table 87. WaVe life Science Main Business
Table 88. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue and Gross Margin (2018-2020E)
Table 89. WaVe life Science Latest Developments
List of Figures
Figure 1. Drugs for Duchenne Muscular Dystrophy (DMD) Report Years Considered
Figure 2. Market Research Methodology
Figure 3. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth Rate 2015-2025 ($ Millions)
Figure 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2015-2020)
Figure 5. Global Eteplirsen Market Size Growth Rate
Figure 6. Global Deflazacort Market Size Growth Rate
Figure 7. Global Ataluren Market Size Growth Rate
Figure 8. Drugs for Duchenne Muscular Dystrophy (DMD) in Hospitals
Figure 9. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Hospitals (2015-2020) ($ Millions)
Figure 10. Drugs for Duchenne Muscular Dystrophy (DMD) in Clinics
Figure 11. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Clinics (2015-2020) ($ Millions)
Figure 12. Drugs for Duchenne Muscular Dystrophy (DMD) in Home Care
Figure 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Home Care (2015-2020) ($ Millions)
Figure 14. Global Home Care YoY Growth ($ Millions)
Figure 15. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application in 2019
Figure 16. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Regions 2015-2020
Figure 17. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2015-2020 ($ Millions)
Figure 18. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2015-2020 ($ Millions)
Figure 19. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2015-2020 ($ Millions)
Figure 20. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2015-2020 ($ Millions)
Figure 21. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Countries in 2019
Figure 22. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type in 2019
Figure 23. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application in 2019
Figure 24. United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 25. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 26. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 27. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Regions in 2019
Figure 28. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type in 2019
Figure 29. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application in 2019
Figure 30. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 31. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 32. Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 33. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 34. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 35. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 36. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Countries in 2019
Figure 37. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type in 2019
Figure 38. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application in 2019
Figure 39. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 40. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 41. UK Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 42. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 43. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 44. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 45. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Countries in 2019
Figure 46. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type in 2019
Figure 47. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application in 2019
Figure 48. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 49. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 50. Israel Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 51. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 52. GCC Countries Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth 2015-2020 ($ Millions)
Figure 53. Global Drugs for Duchenne Muscular Dystrophy (DMD) arket Size Forecast (2021-2025) ($ Millions)
Figure 54. Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 55. APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 56. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 57. Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 58. United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 59. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 60. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 61. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 62. China Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 63. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 64. Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 65. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 66. India Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 67. Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 68. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 69. France Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 70. UK Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 71. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 72. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 73. Spain Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 74. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 75. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 76. Israel Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 77. Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)
Figure 78. GCC Countries Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2021-2025 ($ Millions)


Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets